Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BMS-986148 in Advanced and/or Metastatic Solid Tumors
jRCT2080223357Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986148 in Nonhematologic neoplasms and pleural mesothelioma, sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability of BMS-986148.
02
Drugs
BMS-986148
03
Conditions
Nonhematologic neoplasmspleural mesothelioma
Beyond the preview
Go deeper on jRCT2080223357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223357.